நியாயமான வெளிப்படுத்தல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from நியாயமான வெளிப்படுத்தல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In நியாயமான வெளிப்படுத்தல் Today - Breaking & Trending Today

Viatris Inc. and Biocon Biologics Receive Historic Approval for First Interchangeable Biosimilar Semglee® (insulin glargine-yfgn injection) for the Treatment of Diabetes


Share this article
Share this article
PITTSBURGH and BENGALURU, India, July 28, 2021 /PRNewswire/  Viatris Inc. (NASDAQ: VTRS) and Biocon Biologics Ltd. (a subsidiary of Biocon Ltd.) today announced that the U.S. Food and Drug Administration (FDA) has approved Semglee
® (insulin glargine-yfgn) injection as the first interchangeable biosimilar product under the 351(k) regulatory pathway.
Biocon Biologics
Viatris CEO Michael Goettler commented: We are extremely proud to achieve the industry s first approval of an interchangeable biosimilar product in the U.S., which will help broaden access to this important diabetes medicine for patients, physicians, payers and providers. This is yet another important milestone for our company that not only continues to underscore the strength of our internal scientific capabilities, but also supports our belief in the promising future of our company as we continue to work to identify innovative ways to increase access to co ....

United States , Andhra Pradesh , New Zealand , Kiran Mazumdar Shaw , Rajiv Malik , Arun Chandavarkar , Biocon Biologics , Viatris Biocon Biologics , European Free Trade Association , Exchange Commission , Pfizer Inc , European Union , Viatris Inc , Viatris President Rajiv Malik , Executive Chairperson , Biosimilar Insulin Glargine , Biologics Managing Director Arun Chandavarkar , Biocon Biologic , Global Healthcare , Biologics Limited , Biocon Limited , Generic Formulations , Looking Statements , Private Securities Litigation Reform Act , Fair Disclosure , Neither Biocon ,

Mylan Wins Significant Summary Judgment Rulings in Kansas EpiPen® Class Action


Mylan Wins Significant Summary Judgment Rulings in Kansas EpiPen® Class Action
Company Confident Evidence Regarding Only Remaining Claim Will Show Mylan s Actions Were Lawful and Pro-competitive
News provided by
Share this article
Share this article
PITTSBURGH, June 23, 2021 /PRNewswire/  Viatris (NASDAQ: VTRS) today announced that the U.S. District Court for the District of Kansas ruled, in substantial part, in Mylan s favor on the company s summary judgment motion in the class action related to EpiPen® Auto-Injector.
The company is pleased with the court s decision to dismiss all of the plaintiffs claims under the federal RICO statute, which include claims asserted against Mylan s former CEO Heather Bresch. The court also dismissed claims alleging that Mylan foreclosed branded competition through rebate arrangements with pharmacy benefit managers. ....

United States , Andhra Pradesh , Heather Bresch , Us District Court , Exchange Commission , Pfizer Inc , Viatris Inc , Global Healthcare , Private Securities Litigation Reform Act , Fair Disclosure , ஒன்றுபட்டது மாநிலங்களில் , ஆந்திரா பிரதேஷ் , எங்களுக்கு மாவட்டம் நீதிமன்றம் , பரிமாற்றம் தரகு , ஃபைசர் இன்க் , உலகளாவிய சுகாதாரம் , ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் , நியாயமான வெளிப்படுத்தல் ,